Sodium salt of 2-n-propylthio-6-nitro-1,2,4-triazole[5,1-c]-1,2,4-triazin-7-one dihydrate and sodium salt of 2-n-butylthio-6-nitro-1,2,4-triazole[5,1-c]-1,2,4-triazin-7-one dihydrate

FIELD: chemistry.

SUBSTANCE: invention describes a sodium salt of 2-n-propylthio-6-nitro-1,2,4-triazole[5,1-c]-1,2,4-triazin-7(4H)-one dihydrate and a sodium salt of 2-n-butylthio-6-nitro-1,2,4-triazole[5,1-c]-1,2,4-triazin-7(4H)-one dihydrate having antiviral activity on herpes simplex virus HSV-1.

EFFECT: higher antiviral effect of the compounds.

1 cl, 1 ex, 1 tbl

 

1. The technical field to which the invention relates.

The invention relates to the field of biologically active compounds and relates to di-hydrate of sodium salts 2-propylthio-6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-it 2-butylthio-6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-it is with antiviral action intended for the treatment and prevention of infectious diseases of animals and humans viral nature. The invention can be used in hospitals, research laboratories, as well as in livestock and poultry.

2. The level of technology

There is evidence of antiviral activity of 6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-ones (Synthesis and antiviral activity of 6-nitro-7-oxo-4,7-dihydrooxazolo [5,1-C][1,2,4]triazines. Volturino, Enhamce, Onepager, MBA, Abolution, Nieten etc. / Chemical and pharmaceutical journal. No. 9, 1990, p.41-44).

Currently known sodium salt of 2-methylthio-6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-it (1) dihydrate, which belongs to a series of compounds exhibiting antiviral activity (Onepager, Volturino, Enhamce, Wenchuan, Auero, Oigusele. Sodium salt of 2-methylthio-6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-it, dehydrate, possessing antiviral activity. RF patent №2294936 from 10.03.2007), and can b is to be used in medical practice, livestock and poultry farming.

Sodium salt of 2-methylthio-6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-she dehydrate (1) is a close structural analogue of the claimed compounds and therefore used as a prototype.

3. The invention

The essence of the invention comprise sodium salt of 2-n-propylthio-6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-it is the dihydrate of the formula (2) and the sodium salt of 2-n-butylthio-6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-it is the dihydrate of the formula (3)

4. Information confirming the possibility of carrying out the invention.

4.1. Synthesis of dehydraton sodium salts of 2-alkylthio-6-nitro-1,2,4-triazolo [5,1-C]-1,2,4-triazine-7(4H)-ones (2)

Salt 3 alkylthio-1,2,4-triazolyl-5-page (4,5), obtained from 0.1 mol of the appropriate 5-amino-3-alkylthio-1,2,4-triazole (6,7) (where alkyl, respectively, means n-propyl and n-butyl) effect of 0.1 mol of sodium nitrite or potassium in the presence of 0.25 EQ. acid, using as solvent water ethanol, condense 11 ml (0.1 mol) of ethylnitrosourea in 150 ml of 2 M sodium carbonate solution. The precipitation is filtered off, successively crystallized from 20%acetic acid, water and dried in air. The chemical scheme for the synthesis of the claimed compounds are given below.

Ihad connection (2) is 43%, the output connection (3) - 47%.

Sodium salt of 2-n-propylthio-6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-she dehydrate (2) has the following physicochemical characteristics: TPL>300°C;1H NMR spectrum in DMSO-d6δ, ppm: 3,18 (t, 2H, J=1.5 Hz, CH2), of 1.78 (m, 2H, CH2), was 1.06 (t, 3H, J=1.5 Hz, CH3). Found: 26,56, N - 3,75, N - 26,92. Brutto-formula - C7H11NaO5S. Calculated: C - 26,75, N - 3,53, N - 26,74%.

Sodium salt of 2-n-butylthio-6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-she dehydrate (3) has the following physicochemical characteristics: TPL>300°C;1H NMR spectrum in DMSO-d6δ, ppm: 3,20 (t, 2H, J=1.5 Hz), total 1.74 (m, 2H, CH2), for 1.49 (m, 2H, CH2), is 0.96 (t, 3H, J=1.5 Hz, CH3). Found, %: C - 29,10; N - 4,08; N - 25,46; C8H13N6NaO5S;

Calculated, %: C - To 29.27%; N - 3,99%; N - 25,60%.

The claimed compounds are yellow crystalline high-melting (>300°C) substances soluble in water, methanol, acetone, dimethylformamide, dimethylsulfoxide, and insoluble in benzene, chloroform and most aprotic solvents.

4.2. Antiviral properties of dehydraton sodium salts of 2-alkylthio-6 - nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-ones (2)

Example 1. Determination of antiviral activity of compounds against herpes simplex virus

Cells. Use the built monolayer 24-hour culture of transplantable cells of green monkey kidney Vero.

The viruses. In this work, we used the herpes simplex virus (HSV-1), strain EC.

The maximum tolerated concentration of compounds was determined using the MTT-test in cell culture Vero.

Study the maximum tolerated concentration for the claimed compounds (2,3) and the connection of the prototype (1) showed that the cytotoxicity of the same and is 1000 µg/ml, which allows you to qualify them as low-toxic compounds.

Study of antiviral activity of compounds against herpes simplex virus was carried out on 96-well polystyrene microplate for cell lines Vero. The results were evaluated after 72 hours of culturing the infected cells according to the degree of cytopathic effect caused by virus:

"++++" - more than 90% of the cells have a characteristic change (cytopathic effect)

"+++" about 60% of the cells have a characteristic change;

"++" - less than 20% of the cells have a characteristic change;

"+" is less than 10% of the cells have a characteristic change;

"-" - cells are not changed.

The table shows data on the antiviral activity of the claimed compounds (2,3) and connection-prototype (1) in respect of the herpes simplex virus (HSV-1).

Antiviral activity of compounds against HSV-1
connectionconcentration, mg/mlThe concentration of the virus, lg (TCD50)/ml
321
(1) prototype1000+++++++
500++++++++
200+++++++++
100+++++++++
50+++++++++
20+++++++++
(2)1000---
500---
200++-
100+++++
50++++++
20++++++++
(3)1000---
500---
200+++-
100++++-
50++++++
20++++++++
HSV-1++++ +++++

From the data presented in the table shows that the connection-prototype (1) is practically not active against herpes simplex virus (HSV-1) virus concentration of 3 lg (Tcdo)/ml, even at maximum tolerated concentration (1000 µg/ml). At the same time, the inventive compounds at lower concentrations (500 μg/ml) completely inhibit the cytopathic effect of herpes simplex virus (HSV-1), then there are blees active antiviral compounds compared with the connection of the prototype.

Sodium salt of 2-n-propylthio-6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-she dehydrate and sodium salt of 2-n-butylthio-6-nitro-1,2,4-triazolo[5,1-C]-1,2,4-triazine-7(4H)-she dihydrate



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to novel 1-substituted 3-(2-chloro-1H-indol-3-yl)-4-phenyl-1H-pyrrole-2,5-diones of formula 1: , where R1 denotes H, C1-C6alkyl; R2 denotes compounds which, under the effect of visible light, form fluorescent 2,8-substituted benzo[a]pyrrolo[3,4-c]carbazole-1,3-(2H,8H)diones of formula II: , where R1 and R2 are as described above.

EFFECT: more effective use of the compounds.

10 cl, 2 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medication, reducing desire for alcohol, which represents substituted 1H-benzimidazoles of general formula 1 or their pharmaceutically acceptable salts and/or hydrates, pharmaceutical composition, and medication on their basis. Compounds can be applied in treatment of alcohol abuse with application of ethanol-containing products, if necessary, together with antidepressants. In compounds of general formula 1 , where: W represents sulfur atom or group S=O; R1 represents one or more substituents, selected from hydrogen, halogen, C1-C4alkyl, C1-C4alkyloxy, optionally substituted 5-6-member azaheterocyclyl with 1-2 atoms of nitrogen and/or oxygen in cycle; R2 represents atom of hydrogen or optionally substituted C1-C4alkyl; R3 and R4 independently on each other represent optionally similar substituents, selected from hydrogen, optionally substituted C1-C4alkyl, C3-C6cycloalkyl; R5 represents alkyl substituent, selected from hydrogen or optionally substituted C1-C7alkyl, C1-C7alkenyl, C1-C4alkynyl, optionally substituted phenyl, optionally substituted 5-6-member heterocyclyl with 1-3 heteroatoms, selected from nitrogen, oxygen and sulfur, possibly condensed with benzene ring; C1-C4-alkoxycarbonyl, optionally substituted amino carbonyl, or group CR3R4R together stands for group , where Alk stands for C1-C4alkyl.

EFFECT: medication allows to reduce symptoms of alcohol abuse considerably as compared with earlier known compounds and does not produce unfavorable effect on liver function.

12 cl, 3 tbl, 2 ex, 1 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to pyrrolotriazines of formula (I) , where R1 is selected from a group which includes phenyl, naphthyl, benzyl and heteroaryl, which denotes a mono- or bicyclic radical containing 5-10 ring atoms and up to 2 heteroatoms selected from a group consisting of nitrogen, oxygen and sulphur, at least one ring of which is aromatic, where, if necessary, phenyl and heteroaryl may be substituted with 0, 1 or 2 substitutes independently selected from a group consisting of -(C1-C4)alkyl, where -(C1-C4)alkyl can be substituted with 0, 1, 2 or 3 halogens, 0 or 1 pyrrolidine, -(C1-C3)alkoxy group, where, if necessary, the (C1-C3)alkoxy group may be substituted with a (C1-C3)alkylamino group, halogen, trifluoromethyl, trifluoromethoxy group, phenyl, if necessary substituted with 1 or 2 halogens, - , where X denotes O, nitro group, - (C1-C3)alkylthio group, trifluoromethylthio group, - (C1-C3)alkylcarbonyl, - (C1-C6)alkoxycarbonyl, and a phenoxy group, and where the benzyl can be substituted with 0, 1, 2 or 3 groups selected from a group which includes halogen; R2 is selected from a group consisting of hydrogen, halogen; R3 is selected from a group consisting of carboxyl, - (C1-C6)alkylcarbonyl, - (C3-C6)cycloalkylcarbonyl, - (C1-C6)alkoxycarbonyl, if necessary substituted with 0, 1, 2 or 3 groups selected from a group which includes amino group and (C1-C6)alkoxycarbonyl; aminocarbonyl, -(C1-C6)alkylaminocarbonyl, where (C1-C6)alkylaminocarbonyl which, if necessary, can be substituted with 0, 1, 2 or 3 substitutes independently selected from a group consisting of (C3-C6)cycloalkyl, halogen, amino group, (C1-C6)alkylamino group, hydroxy group, (C1-C6)alkoxy group, (C1-C6))alkoxycarbonyl, (C1-C6)alkylthio group, (C1-C6)alkoxycarbonylamino group,and where, if necessary, (C1-C6)alkylaminocarbonyl may be substituted with 0 or 1 heterocyclyl, which denotes a monocyclic, non-aromatic radical containing 5-8 ring atoms and up to 2 heteroatoms selected from nitrogen and oxygen, where, if necessary, the hetecyclyl may be substituted with 0 or 1 (C1-C6)alkyl, heterocyclylcarbonyl, if necessary substituted with 0 or 1 (C1-C6)alkylamino group, cycloalkyl or (C1-C6)alkyl,where, if necessary, (C1-C6)alkyl may be substituted with 0 or 1 (C1-C6)alkylamino group, and where heterocyclyl denotes a monocyclic, non-aromatic radical containing 5-8 ring atoms and up to 2 heteroatoms selected from nitrogen and oxygen, -(C1-C6)alkyl if necessary substituted with 0, 1 or 2 substitutes independently selected from a group consisting of a) hydroxyl, b) (C1-C6)alkylamino group, where (C1-C6)alkylamino group may be substituted with 0, 1 or 3 substitutes independently selected from a group consisting of halogen, alkylamino group, methoxy group, methylthio group and methylsulphonyl, c) phenylamino group, where the phenylamino group may be substituted with 0, 1 or 2 substitutes independently selected from a group consisting of (C1-C6)alkoxy group and trifluoromethyl, d) heterocyclyl, where heterocyclyl denotes a monocyclic, non-aromatic radical containing 5-8 ring atoms and up to 2 heteroatoms selected from nitrogen and oxygen, and where the heterocyclyl may be substituted with 0 or 1 (C1-C6)alkyl, where (C1-C6)alkyl may be substituted with 0 or 1 methoxy groups or pyridyls, e) imidazolyl, f) pyridylamino group, g) (C1-C3)alkoxy group, if necessary substituted with fluorine or piperidine,where, if necessary, the piperidine may be substituted with 0 or 1 (C1-C6)alkyl, h) (C1-C3)alkoxy(C2-C3)alkoxy group, and i) (C1-C6)alkoxycarbonyl, j) (C3-C6)cycloalkyl, k) cyano group, - (C3-C6)cycloalkylaminocarbonyl, cyano group, heteroaryl, where heteroaryl denotes a monocyclic radical containing 5-6 ring atoms and up to 3 heteroatoms selected from a group consisting of nitrogen and oxygen, the ring of which is aromatic, where the heteroaryl may be substituted with 0, 1 or 2 groups independently selected from a group consisting of q) (C1-C6)alkyl, where the (C1-C6)alkyl may be substituted with 0 or 1 morpholine or 0 or 1 hydroxy group, r) (C1-C6)alkoxycarbonyl, thiophene carbonyl, and R4 is selected from a group consisting of hydrogen; to a pharmaceutically acceptable salt thereof. The invention also pertains to methods of obtaining said compounds.

EFFECT: obtaining novel compounds which can be used in medicine for preventing or treating hyper-proliferative disorders and diseases associated with angiogenesis.

5 cl, 313 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a crystalline form of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one, which exhibits characteristic peaks on an X-ray powder diffraction pattern expressed in two-theta degrees, selected from approximately 7.1, approximately 12.1 and approximately 16.1; or approximately 7.1, approximately 12.1 and approximately 17.5; or approximately 7.1, approximately 12.1 and approximately 23.5; or approximately 12.1, approximately 16.1 and approximately 17.5; or approximately 12.1, approximately 16.1 and approximately 23.5; or approximately 16.1, approximately 17.5 and approximately 23.5; or approximately 7.1, approximately 17.5 and approximately 23.5; or approximately 7.1, approximately 12.1 and approximately 23.5; or approximately 7.1, approximately 16.1 and approximately 23.5, and to a pharmaceutical composition based on said compound, which can be used in medicine to prepare a medicinal agent which acts on the hepatitis C virus (HCV) in HCV-infected mammals.

EFFECT: improved properties of derivatives.

12 cl, 1 tbl, 3 dwg, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel substituted tetracyclic derivatives of tetrahydropyran, pyrrolidine and tetrahydrothiophene of general formula (I), their pharmaceutically acceptable addition salts, their stereochemically isomeric forms, their N-oxide forms, in which all substitutes are defined in claim 1 of the formula of invention. These compounds have binding affinity to serotonin receptors, particularly 5-HT2A and 5-HT2C receptors, and to dopamine receptors particularly D2 dopamine receptors, and have norepiniphrine reuptake inhibition properties. The invention also relates to a pharmaceutical composition containing said compounds, method of preparing said composition and use of said compounds as medicinal agents, particularly for preventing and/or treating several psychiatric and neurological disorders.

EFFECT: new compounds have useful biological properties.

12 cl, 3 tbl, 49 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel substituted 2-alkylamino-3-sulfonyl-pyrazolo[1,5-a]pyrimidines, their pharmaceutically acceptable salts and/or hydrates which have serotonin 5-HT6 receptor antagonist properties and can be used in treating or preventing development of various central nervous system diseases, whose pathogenesis is related to 5-HT6 receptors, particularly Alzheimer's disease, Parkinson's disease, Huntington disease, schizophrenia, other neurodegenerative diseases, cognitive and anxiety disorders and obesity. In general formula (I):

R1 and R3 independently denote optionally identical C1-C3alkyl, R2 is a -(CH2)nX group or R1 and R3 independently denote different substitutes selected from C1-C3 alkyl or a -(CH2)nX group, and R2 is a hydrogen atom or C1-C3alkyl; R4 is C1-C3alkyl; Ri5 is a hydrogen atom, one or two identical or different halogen atoms, C1-C3alkyl; i is equal to 0, 1 or 2; n is equal to 0, 1, 2 or 3; X is a carboxyl CO2H, C1-C3alkyloxycarbonyl, aminocarbonyl CONR6R7 or a NR6R7 amino group; R6 and R7 denote optionally identical hydrogen atom, optionally substituted C1-C3 alkyl, C3-C7cycloalkyl or an optionally substituted 5-7-member azaheterocyclyl containing 1-2 nitrogen atoms in the ring, where the substitutes are selected from C1-C3alkyl; or R6 and R7 together with the nitrogen atom to which they are bonded form an optionally substituted 5-6-member azaheterocyclyl containing 1-2 nitrogen atoms in the ring, where the substitutes are selected from C1-C3alkyl.

EFFECT: obtaining new biologically active compounds.

26 cl, 12 dwg, 4 tbl, 14 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method for synthesis of novel derivatives of benzo[7,8]azonino[5,4-b]indoles, 7,9-etheno-azecino[5,4-b]indoles and 7,9-ethano-azecino[5,4-b]indoles with general structural formulae: , , , I, IV, VII X=H,Y=CO2Me; II, V, VIII X=H, Y=COMe; III, VI, IX X=Y=CO2Me, which have proved to be cytostatic and cytotoxic compounds. The method involves dissolving 3,8,13,13b-tetrahydro-5H-benzo[1,2]indolysino[8,7-b]indole, ethyl eburnamenine-14-carboxylate or methyl (3-α, 14-β, 16α)-14-hydroxy-14,15-dihydro eburnamenine -14-carboxylate in methanol and then reaction with excess dimethyl acetylenedicarboxylate (ADCX) or methyl propiolate or acetyl acetylene, while stirring at +40-+50°C, with subsequent removal of the solvent and grinding the residue in hexane or a mixture of hexane with ethylacetate (ether) or purified using column chromatography on aluminium oxide.

EFFECT: design of an efficient method of obtaining hazardous compounds.

9 ex

FIELD: chemistry.

SUBSTANCE: invention describes novel compounds of general formula: , where R1 - C1-C6alkyl, C1-C6alkoxy, halogen, CN, C(O)NH2 or OCH2CH2OCH3; R2-C1-C6alkyl, possibly substituted with halogen, a halogen, C1-C6alkoxy, phenyl, N(R6)2, (OCH2CH2)nOCH3, O(CH2)mNR7R8, where n equals 1 or 2; m equals 2 or 3; R6 -R7 -C1C6alkyl, and R8 -OCH2CH2OCH3; or R7 and R8 together with the nitrogen atom to which they are bonded form a 6-member heterocycle which additionally contains one oxygen atom or one nitrogen atom, which in the latter case is substituted with C1-C4alkyl; or R1 and R2 together form a 5-member heterocyclic ring system containing two oxygen atoms as heteroatoms; R3 - hydrogen or C1-C6alkyl; R4 - hydrogen, halogen or C1-C6alkoxy; or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing these compounds.

EFFECT: obtaining novel compounds with kinase inhibiting properties, particularly CDK2, or angiogenesis inhibiting properties and can be used in treating malignant growths, particularly in mammary glands, large intestines, lungs and prostate glands.

60 cl, 7 tbl, 101 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, where X is CH; R1 is phenyl or a 6-member heteroaryl which contains 1 or 2 nitrogen atoms as heteroatoms, independently and optionally substituted with up to five groups J; R2 and R3 each independently represents hydrogen, halogen, -V-R or -V-Ra; R5 is R; R is H or an optionally substituted C1-6aliphatic group, where the substitutes are selected from -OR0, phenyl, substituted R0, -N(R0)2; where each independent R0 is selected from hydrogen, halogen, C1-6aliphatic group; Ra is morpholine, V is a bond or Q; Q is -NR5-; each J group independently represents a halogen, -N(R5)2. The invention also relates to a pharmaceutical composition with protein kinase inhibiting properties, and to methods of inhibiting Aurora A protein kinase using the said compounds.

EFFECT: obtaining novel compounds and pharmaceutical compositions based on the said compounds, which can be used in medicine to treat or alleviating a proliferative disorder, such as cancer, in a patient.

25 cl, 2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to pyrido[1,2-a]benzimidazole derivatives of general formula I, where R=alkyl; R1=alkyl, aryl; R2=alkyl. The invention also relates to a method of producing formula I compounds.

EFFECT: novel to pyrido[1,2-a]benzimidazole derivatives with antibacterial activity are obtained.

2 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for treating syphilis and viral diseases specified from influenza, human immunodeficiency virus, cytomegalovirus infections, viral hepatitis type A, D, C and herpes infections, containing an amount of polyphenol compounds of sea buckthorn leaves, including at least 60 % of halloellagotannines, flacoside, a pharmacologically acceptable carrier and a substance of licorice extract, or glycyrrhizic acid, or its pharmaceutically acceptable salt, acridonoacetic acid or its pharmaceutically acceptable salt, birch bark extract or betulin taken in therapeutically effective amounts. A method of treating syphilis and viral diseases, including the introduction of the declared pharmaceutical composition by 2-3 doses 3 times a day.

EFFECT: composition exhibits an evident antiviral action with respect to the infections stated above.

22 cl, 1 dwg, 12 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to orthopedics and can be used for complex therapy in children of early age with cytomegalovirus and locomotor system pathology in case of planned surgery. For this purpose 10 days before taking patient to hospital 1 capsule of eubiotic "Bifiform" is introduced three times a day. Since the day of hospitalisation introduction of the medicine is continued in dose 1 capsule two times a day during 7-10 days. Two days before the operation immunomodulator "Viferon" is introduced in dose 1 suppository a day rectally. 30 minutes before the operation antibiotic "Ceftriaxon" is introduced intravenously in dose 15-20 mg/kg. After operation introduction of "Ceftriaxon" is continued for 2 days. Day dose of "Viferon" is increased to three suppositories every 8 hours during three days. After that it is introduced in dose one suppository per day every second day during 10 days.

EFFECT: elaborated regimen of therapy ensures prevention of post-operation complications, favours faster normalisation of blood parametres and reduction of index of leukocyte intoxication in post-operation period.

FIELD: medicine.

SUBSTANCE: invention refers to medicine and concerns a microbicidal agent delivery systems including a microbicidal composition containing a microbicidal compound which represents a dendrimer including one or more surface groups of formula (IV); its microbicidally active derivative or its pharmaceutically acceptable salt or solvate; and a carrier, an excipient or a diluent for the active compound; and also a preventive device. And the microbicidal composition is applied on a surface of the preventive device and is compatible therewith.

EFFECT: invention provides effective delivery of the microbicidal compositions which are structurally and chemically compatible with the preventive device.

22 cl, 5 ex, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to medical virology. The essence of the invention lies in demonstration of selective antiviral activity in netropsin derivatives: SARC-NT, Pt-bis-NT and 15Lys-bis-NT. Antiviral activity is studied on the example of anti-herpes viral and anti-orthopox viral activity in SARC-NT. A new effect was discovered in the compounds: Pt-bis-NT and 15Lys-bis-NT - anti-orthopox viral activity.

EFFECT: obtaining compounds which provide highly effective inhibition of infections caused by copox and herpes viruses; Pt-bis-NT and 15Lys-bis-NT provide highly effective inhibition of infection caused by cowpox virus; SARC-NT has considerable anti-orthopox viral activity and moderate anti-herpes viral activity; SARC-NT, Pt-bis-NT and 15Lys-bis-NT have potential for use in preparing new antiviral agents.

2 cl, 4 dwg, 1 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention refers to sulphated oligosaccharides of the general formula X-[Y]n-Z-UR1, where X, Y and Z each are the same hexose monosaccharide fragment selected out of group including glucose, mannose, altrose, allose, talose, galactose, idose and gulose, adjoining monosaccharide fragments are bound in 1→2, 1→3, 1→4, and/or 1→6 pattern by glycoside bonds, and each carbon atom not binding X, Y and Z groups is bound by single bond with UR group, with exception for carbon atom in 1 position of Z monosaccharide, to which UR1 group is bound by single bond; where n is an integer within 0 to 6; U is O atom or NH; each R is independently C2-C6-alkenyl, benzyl, SO3M or H, where M is any pharmaceutically acceptable cation of alkali metal or organic amine, or R form N3 together with U; R1 is C1-C12alkyl, benzyl, PEG monomethyl ether or its derivative, C1-C12alkylazide, , or , in the form of ester, free acid, free base or hydrate. Also invention refers to pharmaceutical or veterinary composition based on claimed compounds, for disorder prevention or treatment for mammals in case of proliferate retinopathy, solid tumour and/or metastasis result, coagulation/thrombosis and/or virus infection of organism. Additionally invention refers to application of claimed compounds in medicine production for disorder prevention or treatment for mammals in case of proliferate retinopathy, solid tumour and/or metastasis result, coagulation/thrombosis and/or virus infection of organism.

EFFECT: increased efficiency of compound application in medicine.

11 cl, 3 tbl, 1 dwg, 16 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a composition for prevention and/or treatment of cold-related diseases caused by influenza virus regardless of its serotype, and herpes simplex. The pharmaceutical composition for prevention and/or treatments of cold-related diseases caused by influenza virus regardless of its serotype, and herpes simplex containing as active components a common antiviral agent chosen from the group: tetraxolin, bonaphton, tetrabromtetrahydroxydiphenyl, purified human leucocytic interferon and aqueous or silicone extract of medicinal plant chosen from the group of plants: licorice, Echinacea, aloe, garlic, locoweed, cat's claw, calendula, camomile, linden, birch buds, tea tree in certain ratio. Application of said pharmaceutical composition for prevention and/or treatment of cold-related diseases caused by influenza virus regardless of its serotype, and herpes simplex.

EFFECT: mentioned composition is effective for prevention and/or treatment cold-related diseases caused by influenza virus regardless of its serotype, and herpes simplex virus, ensure short-term evident medical and preventive effect caused by synergism of common antiviral agent and herbal extract.

20 cl, 4 ex

FIELD: medicine.

SUBSTANCE: concept of the invention as technical solution consists in the use of water-spirit 10% of formalin to obtain positive result during herpes therapy and treatment. It is used upon lip tingling. Formalin solution should be applied on the sore place several times a day. The medicine should be used even at the late stage to prevent viruses and cut the likelihood of infection when self treating lip and skin herpes rash there will be no new inflammations and small vesicles with subsequent drying the existing vesicles. The inflammation spots are crusted and then the crust falls off.

EFFECT: obtaining desired result.

FIELD: medicine.

SUBSTANCE: present invention concerns an agent for treatment of virus infectious diseases, namely hepatitis B, hepatitis C, hepatitis D, hepatitis E, retroviruses of group of herpes (herpetic fever, cytomegalovirus) and mainly to a HIV-infection, AIDS, including radon (Rn), differing that in addition silicon (Si), carbon dioxide (CO2) are entered into it at a following parity of components: Rn - 40.0%; Si - 30.0%; CO2 - 30.0%.

EFFECT: working out of a new effective remedy for treatment of virus infectious diseases.

2 cl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to stomatology, and can be used for treatment of herpetic stomatitis. For this purpose lesion focuses of mouth mucosa are cooled by rolling on them roller from permeably-porous titanium nickelide, treated with liquid nitrogen. Rolling is performed without pressing, in reciprocal mode during 2-3 seconds. Then on said focuses Acyclovir ointment is applied.

EFFECT: reduction of terms of disease treatment to 2-3 days due to combined effect of deep cooling of focuses and anti-virus impact of Acyclovir ointment.

2 ex, 3 dwg

FIELD: medicine.

SUBSTANCE: claimed is medication with local action for prevention and treatment of herpes appearance on human lips and skin in form of formaldehyde alcohol-water solution, 100 g of composition containing 8-10 g of formaldehyde and 50 g of ethanol. In unassisted treatment of herpes appearance on human lips and skin, appearance of new inflammations and small vesicles stops, vesicles that appeared dry, with crust, which later falls off, appearing on place of inflammation.

EFFECT: medication is used in liquid form, possesses local activity, hygienic, has unlimited storage term.

FIELD: medicine.

SUBSTANCE: method involves polychemotherapy followed by radiation therapy (RT) with underlying plant-based mouth rinsing and oral administration of Colegel with Derinat and Lidocaine 3 times a day and more often. The polychemotherapy is performed by no more than 2 courses with the radiation started not earlier than in 10-15 days after the polychemotherapy to total basic dose 66-70 Gy and with peripheral blood of an exposed patient analysed for lymphocyte count once in 10 days and more often. If lymphocyte count is 1.2×109/l or less, the following RT sessions are carried out with underlying additional intensive local and system therapy, or the therapy is interrupted for the hemostimulation therapy.

EFFECT: use of the invention allows preventing severity gain in a radiation involvement of oropharyngeal mucosa due to well-timed intensification of local and system therapy, performing a radical RT course and improving clinical effectiveness.

2 cl, 2 ex

Up!